Press Releases

Date Title
10/24/19 Sarepta Therapeutics to Announce Third Quarter 2019 Financial Results and Recent Corporate Developments on November 7, 2019
10/4/19 Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
9/30/19 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/25/19 Sarepta Therapeutics to Announce 9-Month Functional Results from the SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
9/5/19 Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
9/3/19 Sarepta Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
8/30/19 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8/19/19 Sarepta Therapeutics Receives Complete Response Letter from the US Food and Drug Administration for Golodirsen New Drug Application
8/8/19 Sarepta Therapeutics Comments on Erroneous Submission to US FDA Adverse Event Reporting System (FAERS)
8/7/19 Sarepta Therapeutics Announces Second Quarter 2019 Financial Results and Recent Corporate Developments
Displaying 41 - 50 of 635